Drug Use-Results Survey for SYMPROIC Tablets 0.2mg in cancer patients with opioid-induced constipation

Drug Use-Results Survey for SYMPROIC Tablets 0.2mg in cancer patients with opioid-induced constipation - Drug Use-Results Survey for SYMPROIC Tablets 0.2mg in cancer patients with opioid-induced constipation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042851

Enrollment

1200

Registered

2020-12-25

Start date

2018-01-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-induced constipation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patients with opioid-induced constipation who administrate SYMPROIC Tablets for the first time

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Incidence rates of adverse drug reactions	—

Secondary

Measure	Time frame
Improvement rates of frequency and condition of bowel movement (2 weeks later, 4 weeks later, 8 weeks later,12 weeks later or at discontinuation)	—

Countries

Japan

Contacts

Public ContactSayo Hashimoto

Shionogi & Co., Ltd. Pharmacovigilance Department

sayo.hashimoto@shionogi.co.jp+81-6-6209-6990

Outcome results